Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

RCT found enfortumab vedotin significantly prolonged survival vs standard chemotherapy in pts who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor (n=608; median follow up 11.1 months; 12.88 vs 8.97 months; HR, 0.70; P=0.001).

New England Journal of Medicine